Michael Wang

List of Publications by Year
in descending order

200	14,290	47409	25230
papers	citations	49 h-index	113 g-index

204	204	204	12124
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology, 2023, 41, 555-567.	0.8	82
2	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. Journal of Clinical Oncology, 2023, 41, 541-554.	0.8	23
3	Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood, 2022, 139, 666-677.	0.6	27
4	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2022, 40, 202-212.	0.8	34
5	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	2.8	7
6	Ibrutinibâ€“rituximab followed by R-HCVAD as frontline treatment for young patients (â‰¥65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 406-415.	5.1	22
7	Epstein Barr virusâ€“positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Advances, 2022, 6, 891-901.	2.5	2
8	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leukemia and Lymphoma, 2022, 63, 1580-1588.	0.6	0
9	Dual targeting of PI3K and BCLâ€2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma. Journal of Cellular and Molecular Medicine, 2022, , .	1.6	2
10	Mantle cell lymphoma in 2022â€”A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. American Journal of Hematology, 2022, 97, 638-656.	2.0	48
11	Targeting FcÎ³RIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. Journal of Hematology and Oncology, 2022, 15, 42.	6.9	5
12	Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. HemaSphere, 2022, 6, e712.	1.2	21
13	PIK-75 overcomes venetoclax resistance blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma.. American Journal of Cancer Research, 2022, 12, 1102-1115.	1.4	0
14	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discovery, 2022, 3, 385-393.	2.6	29
15	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Therapeutic Advances in Hematology, 2022, 13, 204062072210939.	1.1	7
16	Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. Journal of Medical Economics, 2022, 25, 730-740.	1.0	2
17	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphomaâ€”Finding a Dancing Partner. Current Oncology Reports, 2022, 24, 1299-1311.	1.8	10
18	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 2482-2494.	13.9	83

#	Article	IF	Citations
19	â€œTriple hitâ€•<scp>SOX</scp>11^{â”}, <scp>MME</scp>⁺, <scp>TP53</scp> mutated highâ€grade pleomorphic mantle cell lymphoma. American Journal of Hematology, 2021, 96, 165-166.	2.0	2
20	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. British Journal of Haematology, 2021, 192, e38-e42.	1.2	33
21	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia, 2021, 35, 787-795.	3.3	56
22	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood, 2021, 137, 877-887.	0.6	68
23	Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma. Blood, 2021, 137, 1124-1129.	0.6	7
24	Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. Journal of Medical Economics, 2021, 24, 421-431.	1.0	13
25	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Advances, 2021, 5, 185-197.	2.5	11
26	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom realâ€world analysis of outcomes in 211 patients. British Journal of Haematology, 2021, 193, 290-298.	1.2	32
27	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology, 2021, 96, E137-E140.	2.0	6
28	Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood, 2021, 137, 3272-3276.	0.6	95
29	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet, The, 2021, 397, 892-901.	6.3	260
30	Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma. Cell Reports, 2021, 34, 108870.	2.9	12
31	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. Leukemia, 2021, 35, 3201-3211.	3.3	25
32	Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).. Journal of Clinical Oncology, 2021, 39, 7547-7547.	0.8	9
33	Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leukemia and Lymphoma, 2021, 62, 1325-1334.	0.6	4
34	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature Communications, 2021, 12, 2877.	5.8	35
35	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances, 2021, 5, 2577-2585.	2.5	60
36	CAR T and other Adoptive Cell Therapies for B-cell Malignancies. Journal of the National Cancer Center, 2021, , .	3.0	4

#	Article	IF	Citations
37	CRP and ferritin in addition to the EASIX score predict CAR-Tâ€“related toxicity. Blood Advances, 2021, 5, 2799-2806.	2.5	57
38	Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K Î²/Î´ in relapsed refractory B cell lymphoma. Leukemia and Lymphoma, 2021, 62, 3452-3462.	0.6	4
39	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Modern Pathology, 2021, 34, 2183-2191.	2.9	7
40	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplantation, 2021, 56, 2911-2921.	1.3	21
41	The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. Journal of Hematology and Oncology, 2021, 14, 132.	6.9	16
42	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 720-728.	0.6	7
43	CAR T-Cell Therapies in Mantle Cell Lymphoma, Hints of Cure. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S189-S191.	0.2	2
44	Mantle Cell Lymphoma. Hematologic Malignancies, 2021, , 163-178.	0.2	0
45	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Human Pathology, 2021, 118, 60-68.	1.1	4
46	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. Journal of Hematology and Oncology, 2021, 14, 167.	6.9	21
47	The 5â€year followâ€up of a realâ€world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. British Journal of Haematology, 2021, 192, 1035-1038.	1.2	10
48	Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology and Oncology, 2021, 14, 179.	6.9	33
49	Computer-aided detection of mantle cell lymphoma on F-FDG PET/CT using a deep learning convolutional neural network. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 260-270.	1.0	2
50	Dual Targeting Bcl-2 By Venetoclax and Mcl-1 By AZD5991 to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma. Blood, 2021, 138, 1181-1181.	0.6	0
51	Abemaciclib in Combination with Copanlisib to Overcome Therapeutic Resistance in Mantle Cell Lymphoma. Blood, 2021, 138, 2253-2253.	0.6	1
52	Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma. Blood, 2021, 138, 528-528.	0.6	6
53	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. Blood, 2021, 138, 744-744.	0.6	15
54	Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma. Blood, 2021, 138, 1867-1867.	0.6	2

#	Article	IF	Citations
55	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Blood, 2021, 138, 381-381.	0.6	8
56	Bispecific CD19-CD20 and CD19-CD22 CAR-T Cells with Glycogen Synthase Kinase (GSK)-3Î² Inhibitor TWS119 Treatment Have Superior Therapeutic Effects on Mantle Cell Lymphoma. Blood, 2021, 138, 1698-1698.	0.6	1
57	Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. Blood, 2021, 138, 3525-3525.	0.6	8
58	Acalabrutinib monotherapy in patients with WaldenstrÃ¶m macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematology,the, 2020, 7, e112-e121.	2.2	119
59	Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. , 2020, 8, e001114.		12
60	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. Journal of Clinical Oncology, 2020, 38, 4302-4316.	0.8	22
61	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?. Hematology/Oncology Clinics of North America, 2020, 34, 923-939.	0.9	1
62	Blastoid Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 941-956.	0.9	17
63	Advances in Classification and Treatment of Non-Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 348-356.	1.0	2
64	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet, The, 2020, 396, 839-852.	6.3	1,224
65	Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. Clinical Journal of Oncology Nursing, 2020, 24, 392-398.	0.3	7
66	Advances in the assessment of minimal residual disease in mantle cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 127.	6.9	16
67	Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 3943-3951.	2.5	69
68	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nature Communications, 2020, 11, 4268.	5.8	112
69	Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer Journal, 2020, 10, 33.	2.8	26
70	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2020, 382, 1331-1342.	13.9	1,067
71	Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Advances, 2020, 4, 2927-2938.	2.5	61
72	Second Cancers in a Patient with Gastric MALT Lymphoma. Case Reports in Medicine, 2020, 2020, 1-4.	0.3	0

#	Article	IF	Citations
73	Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Advances, 2020, 4, 2871-2883.	2.5	134
74	A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma. British Journal of Haematology, 2020, 188, e94-e98.	1.2	6
75	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results of the Phase 2 ZUMA-2 Study. Biology of Blood and Marrow Transplantation, 2020, 26, S1.	2.0	4
76	Efficacy of Râ€BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. British Journal of Haematology, 2020, 189, 684-688.	1.2	43
77	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	13.9	1,252
78	Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica, 2020, 105, 1907-1913.	1.7	23
79	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629.	2.0	54
80	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	2.5	43
81	Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. Blood, 2020, 136, 10-11.	0.6	52
82	One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood, 2020, 136, 20-22.	0.6	6
83	Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma. Blood, 2020, 136, 33-33.	0.6	2
84	Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma. Blood, 2020, 136, 35-35.	0.6	1
85	Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma. Blood, 2020, 136, 18-18.	0.6	2
86	Phase I/II study of high dose pomalidomide with Gâ€CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma. American Journal of Hematology, 2020, 95, E232-E235.	2.0	2
87	MCL Cells in Tumor Microenvironment Impair T-Cell Metabolic Fitness and Effector Function. Blood, 2020, 136, 16-16.	0.6	0
88	Targeting the Synthetic Lethality Interaction of MTAP and PRMT5 to Overcome Drug Resistance and Enhance Anti-Cancer Immunity in Mantle Cell Lymphoma. Blood, 2020, 136, 15-15.	0.6	2
89	Targeting Glutamine Metabolism Overcomes Resistance to Targeted Therapies in Refractory Mantle Cell Lymphoma. Blood, 2020, 136, 25-26.	0.6	3
90	Targeting Transcription Checkpoint Using a Novel CDK9 Inhibitor in Mantle Cell Lymphoma. Blood, 2020, 136, 28-29.	0.6	0

#	Article	IF	Citations
91	Interrogation of Dysregulated Pathways Enables Precision Medicine in Mantle Cell Lymphoma. Blood, 2020, 136, 33-33.	0.6	0
92	Xeno-MCL: Genomic, Transcriptomic and Pathologic Landscape Associated with Disease Progression, Clonal Evolution and Tissue Tropism in Patient-Derived Xenografts of Mantle Cell Lymphoma. Blood, 2020, 136, 20-20.	0.6	0
93	Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma. Blood, 2020, 136, 33-34.	0.6	0
94	Overcoming CAR T Resistance with Non-Covalent BTK Inhibitor Loxo-305 in Mantle Cell Lymphoma. Blood, 2020, 136, 10-10.	0.6	1
95	Abemaciclib-Based Combinational Therapies to Overcome Therapeutic Resistance in Mantle Cell Lymphoma. Blood, 2020, 136, 33-34.	0.6	0
96	AZD4320 Is a Novel and Potent BCL-2/XL Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma. Blood, 2020, 136, 44-44.	0.6	1
97	Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Molecular Cancer Therapeutics, 2019, 18, 267-277.	1.9	21
98	Integrated stress response and immune cell infiltration in an ibrutinibâ€refractory mantle cell lymphoma patient following <scp>ONC</scp>201 treatment. British Journal of Haematology, 2019, 185, 133-136.	1.2	11
99	A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. American Journal of Hematology, 2019, 94, E319-E322.	2.0	1
100	A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Blood Cancer Journal, 2019, 9, 80.	2.8	17
101	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia, 2019, 33, 2762-2766.	3.3	67
102	Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma. Science Signaling, 2019, 12, .	1.6	8
103	The modern approach to mantle cell lymphoma. Hematological Oncology, 2019, 37, 66-69.	0.8	22
104	Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine, 2019, 11, .	5.8	161
105	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology, 2019, 94, 710-725.	2.0	151
106	Frontline antibiotic therapy for earlyâ€stage Helicobacter pylori â€negative gastric MALT lymphoma. American Journal of Hematology, 2019, 94, E150-E153.	2.0	7
107	Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 275-284.	0.2	30
108	Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Advances, 2019, 3, 2035-2039.	2.5	12

#	Article	IF	Citations
109	Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer Journal, 2019, 9, 95.	2.8	20
110	SOX11-negative Mantle Cell Lymphoma. American Journal of Surgical Pathology, 2019, 43, 710-716.	2.1	22
111	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. British Journal of Haematology, 2019, 184, 999-1005.	1.2	29
112	Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma. British Journal of Haematology, 2019, 185, 1002-1004.	1.2	2
113	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica, 2019, 104, e211-e214.	1.7	122
114	Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene, 2019, 38, 1802-1814.	2.6	17
115	Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (â‰¥65) Tj ETQq1 1 0.784314 rgBT /O 3988-3988.	0.6	11
116	Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients. Blood, 2019, 134, 3993-3993.	0.6	3
117	Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Clinical Studies, and MD Anderson. Blood, 2019, 134, 1931-1931.	0.6	7
118	Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma. Blood, 2019, 134, 3974-3974.	0.6	0
119	Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clinical Cancer Research, 2018, 24, 3967-3980.	3.2	69
120	The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer Journal, 2018, 8, 33.	2.8	11
121	Can we improve on ibrutinib in mantle cell lymphoma?. Lancet Haematology,the, 2018, 5, e98-e99.	2.2	0
122	Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer, 2018, 124, 2561-2569.	2.0	14
123	Novel chemotherapyâ€free combination regimen for ibrutinibâ€resistant mantle cell lymphoma. British Journal of Haematology, 2018, 181, 561-564.	1.2	7
124	A Systematic Review of Treatments of Relapsed/Refractory Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 13-25.e6.	0.2	14
125	CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Modern Pathology, 2018, 31, 327-336.	2.9	46
126	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet, The, 2018, 391, 659-667.	6.3	324

#	Article	IF	Citations
127	Prospective subgroup analyses of the randomized <scp>MCL</scp>â€002 (<scp>SPRINT</scp>) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology, 2018, 180, 224-235.	1.2	10
128	What is the optimal initial management of the younger mantle cell lymphoma patient?. Best Practice and Research in Clinical Haematology, 2018, 31, 90-98.	0.7	2
129	The B cell receptor signaling pathway in mantle cell lymphoma. Oncotarget, 2018, 9, 25332-25341.	0.8	40
130	Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!. Blood, 2018, 132, 2722-2729.	0.6	59
131	Frontline Treatment for Older Patients with Mantle Cell Lymphoma. Oncologist, 2018, 23, 1337-1348.	1.9	10
132	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Advances, 2018, 2, 2039-2051.	2.5	54
133	Longâ€term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	1.2	81
134	Guideline for the management of mantle cell lymphoma. British Journal of Haematology, 2018, 182, 46-62.	1.2	38
135	Fourâ€year followâ€up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>MCL</scp>). British Journal of Haematology, 2018, 182, 404-411.	1.2	50
136	NF-ÎºB signaling and its relevance to the treatment of mantle cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 83.	6.9	52
137	Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. Journal of Experimental and Clinical Cancer Research, 2018, 37, 150.	3.5	3
138	A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma. British Journal of Haematology, 2018, 182, 63-70.	1.2	11
139	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood, 2018, 132, 4151-4151.	0.6	4
140	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. Blood, 2018, 132, 1599-1599.	0.6	2
141	Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1592-1592.	0.6	6
142	Metabolic Profiling Identifies De Novo Nucleotide Synthesis As a Potential Metabolic Vulnerability for Targeted Therapy Against Mantle Cell Lymphoma. Blood, 2018, 132, 2945-2945.	0.6	1
143	Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. Blood, 2018, 132, 2950-2950.	0.6	1
144	Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nature Communications, 2017, 8, 14920.	5.8	122

#	Article	IF	Citations
145	Novel agents in mantle cell lymphoma. Expert Review of Anticancer Therapy, 2017, 17, 491-506.	1.1	7
146	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood, 2017, 129, 3175-3183.	0.6	126
147	Ultraâ€“lowâ€dose radiotherapy for definitive management of ocular adnexal Bâ€cell lymphoma. Head and Neck, 2017, 39, 1095-1100.	0.9	87
148	B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. Clinical Cancer Research, 2017, 23, 4212-4223.	3.2	49
149	Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three openâ€label studies. British Journal of Haematology, 2017, 179, 430-438.	1.2	116
150	Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). Journal of Hematology and Oncology, 2017, 10, 171.	6.9	41
151	Smoldering mantle cell lymphoma. Journal of Experimental and Clinical Cancer Research, 2017, 36, 185.	3.5	31
152	Abstract 3651: Preclinical examination of the effects of MT-3724, an engineered toxin body targeting CD20, in mantle cell lymphoma. , 2017, , .		2
153	Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget, 2017, 8, 112516-112529.	0.8	32
154	Elotuzumab for the treatment of multiple myeloma. Journal of Hematology and Oncology, 2016, 9, 55.	6.9	36
155	Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. Journal of Hematology and Oncology, 2016, 9, 51.	6.9	112
156	Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2914-2916.	0.6	24
157	Postibrutinib outcomes in patients with mantle cell lymphoma. Blood, 2016, 127, 1559-1563.	0.6	228
158	Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. British Journal of Haematology, 2016, 173, 884-895.	1.2	29
159	Rituximab plus hyperâ€‹<scp>CVAD</scp> alternating with <scp>MTX</scp>/Araâ€C in patients with newly diagnosed mantle cell lymphoma: 15â€year followâ€up of a phase <scp>II</scp> study from the <scp>MD</scp> Anderson Cancer Center. British Journal of Haematology, 2016, 172, 80-88.	1.2	82
160	ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma. Critical Reviews in Oncology/Hematology, 2016, 107, 14-19.	2.0	17
161	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. Haematologica, 2016, 101, 235-240.	1.7	24
162	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology, The, 2016, 17, 200-211.	5.1	373

#	Article	IF	Citations
163	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. Journal of the National Cancer Institute, 2016, 108, .	3.0	49
164	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, The, 2016, 387, 770-778.	6.3	389
165	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002;) Tj ETQq1 1 0.784314 rgBT /Over	5.1	135
166	Mantle Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 1256-1269.	0.8	247
167	Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 48-56.	5.1	189
168	Chemotherapy-Free Induction with Ibrutinib-Rituximab Followed By Shortened Cycles of Chemo-Immunotherapy Consolidation in Young, Newly Diagnosed Mantle Cell Lymphoma Patients: A Phase II Clinical Trial. Blood, 2016, 128, 147-147.	0.6	10
169	Pre-Clinical Evaluation of the PI3K-p110Î²/Î´ Inhibitor KA2237 in Mantle Cell Lymphoma. Blood, 2016, 128, 1837-1837.	0.6	5
170	Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget, 2016, 7, 58638-58648.	0.8	34
171	CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget, 2016, 7, 73558-73572.	0.8	61
172	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood, 2015, 126, 1565-1574.	0.6	92
173	Mantle cell lymphoma: evolving management strategies. Blood, 2015, 125, 48-55.	0.6	155
174	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood, 2015, 126, 739-745.	0.6	349
175	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Letters, 2015, 357, 179-185.	3.2	81
176	Involvement of tumor-associated macrophage activationin vitroduring development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leukemia and Lymphoma, 2015, 56, 186-193.	0.6	11
177	Ibrutinibâ€associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. British Journal of Haematology, 2015, 170, 131-134.	1.2	15
178	Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. British Journal of Haematology, 2015, 168, 55-62.	1.2	44
179	Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). Blood, 2015, 126, 469-469.	0.6	3
180	CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget, 2015, 6, 36032-36040.	0.8	10

#	Article	IF	Citations
181	Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget, 2014, 5, 7368-7380.	0.8	7
182	Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial. British Journal of Haematology, 2014, 165, 575-578.	1.2	34
183	Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. British Journal of Haematology, 2014, 165, 510-518.	1.2	34
184	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2014, 106, .	3.0	88
185	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2013, 369, 507-516.	13.9	1,449
186	Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncology, The, 2012, 13, 716-723.	5.1	274
187	Indolent mantle cell lymphoma. Haematologica, 2011, 96, 1086-1088.	1.7	27
188	Evidence of a Role for Activation of Wnt/Î²-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. Journal of Biological Chemistry, 2011, 286, 11009-11020.	1.6	114
189	Expression of B7-H1 in Mantle Cell Lymphoma Leads to Inhibition of T Cell Response to Tumor Cells. Blood, 2011, 118, 2643-2643.	0.6	0
190	Tenâ€year followâ€up after intense chemoimmunotherapy with Rituximabâ€HyperCVAD alternating with Rituximabâ€high dose methotrexate/cytarabine (Râ€MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. British Journal of Haematology, 2010, 150, 200-208.	1.2	213
191	Phase I trial of bortezomib in combination with rituximabâ€HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. British Journal of Haematology, 2010, 151, 47-53.	1.2	49
192	Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2010, 151, 346-353.	1.2	63
193	Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1419-1427.	2.0	93
194	Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer, 2008, 113, 791-798.	2.0	219
195	Phase 2 trial of rituximab plus hyperâ€CVAD alternating with rituximab plus methotrexateâ€cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer, 2008, 113, 2734-2741.	2.0	31
196	A Severe Combined Immunodeficientâ€“hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Clinical Cancer Research, 2008, 14, 2154-2160.	3.2	26
197	Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. Blood, 2008, 112, 3051-3051.	0.6	5
198	Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood, 2007, 109, 5455-5462.	0.6	41

#	Article	IF	Citations
199	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. Blood, 2007, 110, 3032-3032.	0.6	1
200	High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. Journal of Clinical Oncology, 2005, 23, 7013-7023.	0.8	523